cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates

David N. Louis, David W. Ellison, Daniel J. Brat, Kenneth Aldape, David Capper, Cynthia Hawkins, Werner Paulus, Arie Perry, Guido Reifenberger, Dominique Figarella-Branger, Andreas von Deimling, Pieter Wesseling

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary.
Original languageEnglish
JournalBrain Pathology
DOIs
Publication statusPublished - 2019

Cite this

Louis, David N. ; Ellison, David W. ; Brat, Daniel J. ; Aldape, Kenneth ; Capper, David ; Hawkins, Cynthia ; Paulus, Werner ; Perry, Arie ; Reifenberger, Guido ; Figarella-Branger, Dominique ; von Deimling, Andreas ; Wesseling, Pieter. / cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. In: Brain Pathology. 2019.
@article{dbd8397d60cc496aa11f4f74a1d4226c,
title = "cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates",
abstract = "cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary.",
author = "Louis, {David N.} and Ellison, {David W.} and Brat, {Daniel J.} and Kenneth Aldape and David Capper and Cynthia Hawkins and Werner Paulus and Arie Perry and Guido Reifenberger and Dominique Figarella-Branger and {von Deimling}, Andreas and Pieter Wesseling",
year = "2019",
doi = "10.1111/bpa.12732",
language = "English",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",

}

Louis, DN, Ellison, DW, Brat, DJ, Aldape, K, Capper, D, Hawkins, C, Paulus, W, Perry, A, Reifenberger, G, Figarella-Branger, D, von Deimling, A & Wesseling, P 2019, 'cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates' Brain Pathology. https://doi.org/10.1111/bpa.12732

cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. / Louis, David N.; Ellison, David W.; Brat, Daniel J.; Aldape, Kenneth; Capper, David; Hawkins, Cynthia; Paulus, Werner; Perry, Arie; Reifenberger, Guido; Figarella-Branger, Dominique; von Deimling, Andreas; Wesseling, Pieter.

In: Brain Pathology, 2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates

AU - Louis, David N.

AU - Ellison, David W.

AU - Brat, Daniel J.

AU - Aldape, Kenneth

AU - Capper, David

AU - Hawkins, Cynthia

AU - Paulus, Werner

AU - Perry, Arie

AU - Reifenberger, Guido

AU - Figarella-Branger, Dominique

AU - von Deimling, Andreas

AU - Wesseling, Pieter

PY - 2019

Y1 - 2019

N2 - cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary.

AB - cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85066133531&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31038238

U2 - 10.1111/bpa.12732

DO - 10.1111/bpa.12732

M3 - Review article

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

ER -